{"id":19085,"date":"2024-12-20T21:30:26","date_gmt":"2024-12-20T13:30:26","guid":{"rendered":"https:\/\/flcube.com\/?p=19085"},"modified":"2024-12-20T21:30:28","modified_gmt":"2024-12-20T13:30:28","slug":"sichuan-kelun-biotech-launches-sacituzumab-tirumotecan-for-triple-negative-breast-cancer-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19085","title":{"rendered":"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China"},"content":{"rendered":"\n

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990<\/a>) has announced the commercial launch of its sacituzumab tirumotecan (SKB264\/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two kinds of systematic treatment, including at least one for an advanced or metastatic stage. The marketing approval for this innovative treatment was secured just last month.<\/p>\n\n\n\n

First Domestically Developed ADC Fully Approved in China<\/strong>
Sacituzumab tirumotecan (SKB264\/MK-2870), a TROP2-targeted antibody drug conjugate (ADC), represents a breakthrough in cancer therapeutics. It was the subject of a licensing deal between Merck, Sharp & Dohme (MSD) for territories outside Greater China in May 2022. This drug stands as the first home-grown ADC to receive full regulatory approval in China, indicating a new era in domestic pharmaceutical innovation and development.<\/p>\n\n\n\n

Implications for Cancer Treatment and the Pharmaceutical Industry<\/strong>
The launch of sacituzumab tirumotecan by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd is expected to have a profound impact on the treatment landscape for TNBC. By offering a new treatment option for patients with limited therapeutic alternatives, this ADC has the potential to improve patient outcomes and enhance the standard of care. This advancement is also a testament to the growing capabilities of China’s pharmaceutical sector to develop and bring to market complex, targeted therapies.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its…<\/p>\n","protected":false},"author":1,"featured_media":19086,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,971,1832,40],"class_list":["post-19085","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-hkg-6990","tag-kelun-biotech-biopharmaceutical","tag-market-launch"],"yoast_head":"\nSichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264\/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two kinds of systematic treatment, including at least one for an advanced or metastatic stage. The marketing approval for this innovative treatment was secured just last month.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19085\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China\" \/>\n<meta property=\"og:description\" content=\"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264\/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two kinds of systematic treatment, including at least one for an advanced or metastatic stage. The marketing approval for this innovative treatment was secured just last month.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19085\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-20T13:30:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-20T13:30:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2001-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"516\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China\",\"datePublished\":\"2024-12-20T13:30:26+00:00\",\"dateModified\":\"2024-12-20T13:30:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2001-1.png\",\"keywords\":[\"ADC \\\/ XDC\",\"HKG: 6990\",\"Kelun-Biotech Biopharmaceutical\",\"Market launch\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19085#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19085\",\"name\":\"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2001-1.png\",\"datePublished\":\"2024-12-20T13:30:26+00:00\",\"dateModified\":\"2024-12-20T13:30:28+00:00\",\"description\":\"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264\\\/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two kinds of systematic treatment, including at least one for an advanced or metastatic stage. The marketing approval for this innovative treatment was secured just last month.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19085\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2001-1.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2001-1.png\",\"width\":1080,\"height\":516,\"caption\":\"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19085#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China - Insight, China's Pharmaceutical Industry","description":"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264\/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two kinds of systematic treatment, including at least one for an advanced or metastatic stage. The marketing approval for this innovative treatment was secured just last month.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19085","og_locale":"en_US","og_type":"article","og_title":"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China","og_description":"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264\/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two kinds of systematic treatment, including at least one for an advanced or metastatic stage. The marketing approval for this innovative treatment was secured just last month.","og_url":"https:\/\/flcube.com\/?p=19085","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-20T13:30:26+00:00","article_modified_time":"2024-12-20T13:30:28+00:00","og_image":[{"width":1080,"height":516,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2001-1.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19085#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19085"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China","datePublished":"2024-12-20T13:30:26+00:00","dateModified":"2024-12-20T13:30:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19085"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19085#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2001-1.png","keywords":["ADC \/ XDC","HKG: 6990","Kelun-Biotech Biopharmaceutical","Market launch"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19085#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19085","url":"https:\/\/flcube.com\/?p=19085","name":"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19085#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19085#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2001-1.png","datePublished":"2024-12-20T13:30:26+00:00","dateModified":"2024-12-20T13:30:28+00:00","description":"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264\/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two kinds of systematic treatment, including at least one for an advanced or metastatic stage. The marketing approval for this innovative treatment was secured just last month.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19085#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19085"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19085#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2001-1.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2001-1.png","width":1080,"height":516,"caption":"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19085#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2001-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19085"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19085\/revisions"}],"predecessor-version":[{"id":19087,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19085\/revisions\/19087"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19086"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}